Exelixis Inc v. Handa Pharma Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Exelixis, Inc. (Delaware)
  • Defendant: Handa Pharmaceuticals, Inc. (Taiwan); Handa Pharma, Inc. (Delaware); Handa Oncology, LLC (California)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
• Case Identification: 1:26-cv-00813, D. Del., 07/06/2026
• Venue Allegations: Venue is alleged to be proper in the District of Delaware because Defendant Handa Pharma is a Delaware corporation and therefore resides in the district, and because Defendant Handa Pharmaceuticals is not a U.S. resident and may be sued in any judicial district.
• Core Dispute: Plaintiff alleges that Defendants' submission of a 505(b)(2) New Drug Application to the FDA for approval to market and sell cabozantinib capsules constitutes an act of infringement of five U.S. patents covering processes for manufacturing cabozantinib.
• Technical Context: The technology at issue involves chemical synthesis processes for producing cabozantinib, an active pharmaceutical ingredient used as a c-MET modulator in blockbuster oncology drugs for treating various cancers.
• Key Procedural History: This action arises under the Hatch-Waxman Act following Defendants' submission of a New Drug Application for a generic version of Plaintiff's CABOMETYX® drug. The complaint details extensive but unsuccessful pre-suit negotiations between the parties, during which Plaintiff sought access to Defendants' confidential manufacturing information to confirm infringement of its process patents. Plaintiff's allegations are therefore premised on publicly available information, including a patent publication by Defendants.

Case Timeline

Date	Event
2003-09-26	U.S. Patent No. 9,174,947 Priority Date
2009-08-07	U.S. Patent No. 10,736,886 Priority Date
2011-02-10	U.S. Patent No. 10,123,999 Priority Date
2011-10-20	U.S. Patent No. 9,365,516 Priority Date
2012-10-22	U.S. Patent No. 9,969,692 Priority Date
2015-11-03	U.S. Patent No. 9,174,947 Issued
2016-04-25	Exelixis's CABOMETYX® initially approved by FDA
2016-06-14	U.S. Patent No. 9,365,516 Issued
2018-05-15	U.S. Patent No. 9,969,692 Issued
2018-11-13	U.S. Patent No. 10,123,999 Issued
2020-08-11	U.S. Patent No. 10,736,886 Issued
2025-09-29	Handa submits 505(b)(2) NDA to the FDA
2025-11-25	Handa sends Paragraph IV Notice Letter to Exelixis
2026-04-15	Date by which Handa allegedly had knowledge of the Asserted Patents
2026-07-06	Complaint Filing Date
2026-07-29	Handa's PDUFA target review completion date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,174,947 - "c-MET MODULATORS AND METHODS OF USE"

• Patent Identification: U.S. Patent No. 9,174,947, "c-MET MODULATORS AND METHODS OF USE," issued November 3, 2015 Compl. ¶26

The Invention Explained

• Problem Addressed: The patent describes various chemical compounds that are useful as modulators of protein kinase enzymatic activity, particularly for kinases like c-Met, KDR, and flt-3, which are implicated in cancer '947 Patent, abstract '947 Patent, col. 1:20-41 Efficient and reliable processes are needed to synthesize these therapeutically important compounds.
• The Patented Solution: The patent claims specific chemical processes for preparing quinoline and quinazoline derivatives, which are classes of c-Met modulators '947 Patent, col. 1:42-45 The claimed process involves reacting a quinoline or quinazoline compound having a leaving group (like chlorine) at the 4-position with a substituted aminophenol derivative to form an ether linkage, a key step in building the final cabozantinib molecule '947 Patent, col. 177:45-178:44
• Technical Importance: The invention provides a defined synthetic pathway for producing c-Met modulators, which are crucial components of targeted cancer therapies like Plaintiff's blockbuster drug, CABOMETYX® Compl. ¶24

Key Claims at a Glance

• The complaint asserts claims 1-5 Compl. ¶69 Claim 1 is the independent claim.
• Essential elements of independent claim 1 include:
  • A process for preparing a compound of formula I.
  • The process comprises reacting a compound of formula f(1) with a reactant y(1).
  • The reaction occurs in the presence of a non-nucleophilic base which is an alkali metal alkoxide.
  • The process further comprises contacting the resulting compound g(1) with a reactant z(1) to yield the compound of formula I.
• The complaint does not explicitly reserve the right to assert dependent claims for this patent, but the assertion of claims 1-5 implies this.

U.S. Patent No. 9,365,516 - "PROCESS FOR PREPARING QUINOLINE DERIVATIVES"

• Patent Identification: U.S. Patent No. 9,365,516, "PROCESS FOR PREPARING QUINOLINE DERIVATIVES," issued June 14, 2016 Compl. ¶27

The Invention Explained

• Problem Addressed: The patent background describes the need for new and efficient processes for making quinoline derivatives that are useful as protein kinase inhibitors for treating cancer '516 Patent, col. 1:21-30
• The Patented Solution: The '516 Patent discloses a specific, multi-step process for preparing quinoline compounds '516 Patent, abstract The process involves steps such as contacting 1,1-cyclopropane dicarboxylic acid with thionyl chloride, and then coupling the resulting intermediate with an amine to form a key building block (an amide), which is subsequently coupled with another part of the molecule to form the final quinoline derivative '516 Patent, col. 2:50-4:1
• Technical Importance: This process provides a method for assembling complex quinoline-based kinase inhibitors, which are valuable therapeutic agents for cancer treatment Compl. ¶24

Key Claims at a Glance

• The complaint asserts claims 23-24 Compl. ¶83 Claim 23 is the independent claim.
• Essential elements of independent claim 23 include:
  • A process for preparing a compound of Formula I.
  • The process comprises (a) contacting 1,1-cyclopropane dicarboxylic acid with thionyl chloride in a polar aprotic solvent.
  • The process further comprises (b) adding a specific amine and a tertiary amine base to the mixture of step (a) to form a compound of Formula A.
  • The process further comprises (c) coupling the compound of Formula A with an amine of Formula B to form the compound of Formula I.
• The complaint does not explicitly reserve the right to assert dependent claims for this patent.

U.S. Patent No. 9,969,692 - "Process for preparing quinoline derivatives"

• Patent Identification: U.S. Patent No. 9,969,692, "Process for preparing quinoline derivatives," issued May 15, 2018 Compl. ¶28
• Technology Synopsis: The patent claims processes for manufacturing cabozantinib free base and its salt forms, such as cabozantinib (L)-malate Compl. ¶101 These processes are central to producing the active ingredient in Plaintiff's and Defendants' products.
• Asserted Claims: Claims 1-21 are asserted Compl. ¶97
• Accused Features: The manufacturing process for the Handa Cabozantinib Product is alleged to infringe, based on publicly available information from a patent publication attributed to Handa Compl. ¶100

U.S. Patent No. 10,123,999 - "Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds"

• Patent Identification: U.S. Patent No. 10,123,999, "Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds," issued November 13, 2018 Compl. ¶29
• Technology Synopsis: The patent covers processes for preparing quinoline compounds, including cabozantinib free base and its (L)-malate salt '999 Patent, col. 3:35-42 This synthesis is a key part of manufacturing the active ingredient.
• Asserted Claims: Claims 1-11 are asserted Compl. ¶112
• Accused Features: The complaint alleges that the manufacturing process for the Handa Cabozantinib Product infringes, premised on information from a patent publication attributed to Handa Compl. ¶115

U.S. Patent No. 10,736,886 - "Methods of using c-MET modulators"

• Patent Identification: U.S. Patent No. 10,736,886, "Methods of using c-MET modulators," issued August 11, 2020 Compl. ¶30
• Technology Synopsis: Although titled as a method of use patent, the complaint asserts process claims from this patent directed to preparing cabozantinib free base and its (L)-malate salt form Compl. ¶130
• Asserted Claims: Claims 1-6 are asserted Compl. ¶126
• Accused Features: The manufacturing process for the Handa Cabozantinib Product is alleged to infringe, based on publicly available information from a patent publication attributed to Handa Compl. ¶129

III. The Accused Instrumentality

Product Identification

The accused instrumentality is the "Handa Cabozantinib Product," which are capsules containing cabozantinib for the treatment of cancer Compl. ¶1

Functionality and Market Context

The Handa Cabozantinib Product is a proposed generic drug containing "cabozantinib in the form of cabozantinib lauryl sulfate" in 11.5 mg, 23 mg, and 34.5 mg dosage strengths Compl. ¶37 Compl. ¶35 It is intended to be a generic equivalent to Exelixis's CABOMETYX®, a "blockbuster drug" for treating multiple forms of cancer Compl. ¶24 Compl. ¶37 Handa is seeking FDA approval via a 505(b)(2) New Drug Application (NDA) and has stated its intention to launch the product in the U.S. immediately upon approval, which could be as early as late July 2026 Compl. ¶1 Compl. ¶57 Compl. ¶59

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint's infringement theory is brought under 35 U.S.C. § 271(g), which makes it an act of infringement to import, offer to sell, sell, or use within the U.S. a product which is made by a process patented in the U.S. Compl. ¶69 Exelixis alleges that Handa's product is manufactured abroad using processes claimed in the Asserted Patents and is then imported into the U.S. Compl. ¶77 Lacking access to Handa's confidential manufacturing information, Exelixis bases its infringement allegations on publicly available information, primarily U.S. Patent No. 12,064,430 (the "Handa Publication"), which allegedly describes processes for making cabozantinib lauryl sulfate Compl. ¶39

'947 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A process for preparing a compound of formula I...	The complaint alleges Handa uses a process to manufacture cabozantinib, a compound of formula I, for its Handa Cabozantinib Product.	¶39; ¶72	col. 15:50-16:55
...the process comprising: reacting a compound of formula f(1) with a reactant y(1) in the presence of a non-nucleophilic base which is an alkali metal alkoxide to yield the compound of formula g(1)	The complaint does not provide sufficient detail for analysis of this specific element.		col. 33:36-34:21
...and contacting a compound of formula g(1) with a reactant z(1) to yield the compound of formula I...	The complaint alleges that the process described in the Handa Publication, which involves preparing cabozantinib lauryl sulfate from cabozantinib free base, practices the claimed process steps.	¶74	col. 33:36-34:21

'516 Patent Infringement Allegations

Claim Element (from Independent Claim 23)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A process for preparing a compound of Formula I...	The complaint alleges Handa uses a process to manufacture cabozantinib, a compound of Formula I, for its Handa Cabozantinib Product.	¶39; ¶86	col. 1:49-2:51
...comprising (a) contacting 1,1-cyclopropane dicarboxylic acid with thionyl chloride in a polar aprotic solvent...	The complaint does not provide sufficient detail for analysis of this specific element.		col. 3:61-4:12
...(b) adding [an amine] and a tertiary amine base to the mixture of step (a) to form a compound of Formula A...	The complaint does not provide sufficient detail for analysis of this specific element.		col. 3:61-4:12
...(c) coupling a compound of Formula A with an amine of Formula B to form a compound of Formula I.	The complaint alleges that the process described in the Handa Publication for preparing cabozantinib lauryl sulfate from cabozantinib free base practices the claimed coupling steps.	¶88	col. 3:61-4:12

• Identified Points of Contention:
  • Evidentiary Question: The complaint is premised on the belief that the process described in the "Handa Publication" reflects Handa's actual commercial manufacturing process for its cabozantinib product Compl. ¶39 Compl. ¶56 A primary point of contention will be what evidence supports this connection, particularly as Handa has allegedly refused to provide its confidential process information Compl. ¶52
  • Scope Question (§ 271(g)): Exelixis alleges that Handa's subsequent conversion of cabozantinib into cabozantinib lauryl sulfate for its final product "does not constitute a material change" that would defeat infringement under 35 U.S.C. § 271(g)(1) Compl. ¶78 Compl. ¶92 This raises the question of whether the chemical modification to a different salt form is significant enough to break the causal chain from the patented process to the imported product.
  • Technical Question: The complaint alleges infringement based on processes described in the Handa Publication for making cabozantinib lauryl sulfate from cabozantinib or cabozantinib (L)-malate Compl. ¶39 The analysis will question whether the specific reactants, conditions, and reaction mechanisms disclosed in that publication align with the limitations of the asserted claims in the '947 and '516 patents.

V. Key Claim Terms for Construction

• The Term: "convergent process"

• Context and Importance: During pre-suit correspondence, Handa allegedly distinguished its activities by citing a different publication (WO'400) that discloses a "linear process for making cabozantinib that differs from the convergent process claimed in the Asserted Patents" Compl. ¶54 This exchange suggests the distinction between "convergent" and "linear" synthesis pathways may be a central issue for determining infringement. Practitioners may focus on this term because the parties have already framed a potential non-infringement argument around it.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The '516 patent specification does not appear to provide an explicit definition of "convergent process." A party might argue for a broad, conventional chemical meaning, encompassing any process where two or more complex, pre-synthesized fragments are joined late in the synthesis to form the final molecule.
  • Evidence for a Narrower Interpretation: The '516 patent's examples and detailed description illustrate a specific sequence of coupling reactions '516 Patent, col. 25:4-28:28 A party might argue that "convergent process" should be limited to the specific type of fragment coupling shown in the patent's embodiments, potentially excluding other multi-fragment assembly strategies.

• The Term: "reacting"

• Context and Importance: This term appears in claim 1 of the '947 Patent and is fundamental to the claimed chemical transformation. The scope of "reacting" will be critical to determining whether the alleged process from the Handa Publication, which may use different specific reagents or conditions, falls within the claim.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The specification describes the reaction being carried out under "suitable reaction conditions," with "non-limiting examples" including various inorganic bases and solvents '947 Patent, col. 9:28-38 This language may support an interpretation that "reacting" covers a wide range of conditions that achieve the claimed chemical conversion.
  • Evidence for a Narrower Interpretation: The patent provides specific examples with defined reactants, temperatures, and solvents (e.g., '947 Patent, col. 177:45-178:44). A party could argue that "reacting" should be construed more narrowly in light of these specific disclosed embodiments, potentially limiting the claim to processes that are highly similar to those explicitly described.

VI. Other Allegations

• Indirect Infringement: The complaint focuses on direct infringement under 35 U.S.C. § 271(g). However, it alleges that the various Handa entities are "intertwined and collaborate" and "work in concert" in the development, manufacture, and planned sale of the accused product Compl. ¶10 Compl. ¶13 These allegations could potentially form the basis for later claims of joint or indirect infringement among the related corporate defendants.
• Willful Infringement: The complaint alleges that Handa had "actual notice of the '947 patent" during pre-suit communications and that Exelixis "timely gave Handa actual notice" of all asserted patents Compl. ¶71 Compl. ¶85 Compl. ¶99 Compl. ¶114 Compl. ¶128 It specifically alleges that Handa had knowledge of the patents at least as of April 15, 2026 Compl. ¶53 These allegations of pre-suit knowledge may support a claim for willful infringement.

VII. Analyst's Conclusion: Key Questions for the Case

1. A central evidentiary question will be one of "process identity": will discovery confirm that Handa's actual commercial manufacturing process is equivalent to the processes described in the Handa Publication, and does that process, in turn, read on the specific steps required by Exelixis's asserted claims?

2. A key legal question will be one of "statutory scope under 35 U.S.C. § 271(g)": does the chemical conversion of cabozantinib (the alleged product of the patented process) into cabozantinib lauryl sulfate (the active ingredient in the imported product) constitute a "material change" sufficient to shield the final imported product from infringement?

3. A pivotal issue of "claim construction" may arise from Handa's pre-suit assertion that it uses a "linear process" as distinct from the "convergent process" allegedly claimed in the patents. The case may turn on whether the court construes these terms broadly enough to cover Handa's synthesis pathway, or narrowly, in a way that allows Handa to design around the claims.